Sugi Predict

Sugi Predict / Compounds / SCHEMBL11911697

SCHEMBL11911697

SCHEMBL11911697

COc1ccc(-c2coc3c4c(c(CC=C(C)C)c(O)c3c2=O)OC(C)(C)C=C4)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.84
▸ MAPT P10636 6/20 0.84
▸ PTPN1 P18031 6/20 0.84
▸ ALDH1A1 P00352 4/20 0.84
▸ USP2 O75604 4/20 0.84
▸ KMT2A Q03164 4/20 0.84
▸ MAPK1 P28482 3/20 0.84
▸ MEN1 O00255 3/20 0.84
▸ ALOX15 P16050 3/20 0.84
▸ TP53 P04637 3/20 0.84
▸ SMN1; SMN2 Q16637 3/20 0.84
▸ HDAC3 O15379 2/20 0.84
▸ HDAC4 P56524 2/20 0.84
▸ HDAC1 Q13547 2/20 0.84
▸ HDAC7 Q8WUI4 2/20 0.84
▸ HDAC2 Q92769 2/20 0.84
▸ HDAC10 Q969S8 2/20 0.84
▸ HDAC11 Q96DB2 2/20 0.84
▸ HDAC8 Q9BY41 2/20 0.84
▸ HDAC6 Q9UBN7 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15942840 0.93 PTPN1 (0.77) CYP3A4MAPTPTPN1ALDH1A1USP2
Osajin SCHEMBL22093541 0.92 PTPN1 (0.95) CYP3A4MAPTPTPN1ALDH1A1USP2
Osajin SCHEMBL571689 0.91 PTPN1 (1.00) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL18906967 0.90 PTPN1 (0.88) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL11911698 0.89 CYP3A4 (0.79) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL24305657 0.88 CYP3A4 (0.83) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL22108476 0.88 CYP3A4 (0.83) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL24305495 0.88 PTPN1 (0.75) CYP3A4MAPTPTPN1ALDH1A1USP2
Osajin SCHEMBL27659828 0.88 PTPN1 (0.93) CYP3A4MAPTPTPN1ALDH1A1USP2
SCHEMBL11911699 0.88 CYP3A4 (0.77) CYP3A4MAPTPTPN1ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119399-A1 COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-04-21 — — US disclosed
US-20220119399-A1 COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-04-21 — — US disclosed
WO-2020123699-A1 COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-06-18 — — WO disclosed
US-9974766-B2 Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) 2018-05-22 — — US disclosed
US-9974766-B2 Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (MO) 2018-05-22 — — US disclosed
US-9822125-B2 Benzopyran compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2017-11-21 — — US disclosed
US-9822125-B2 Benzopyran compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2017-11-21 — — US disclosed
US-20170151212-A1 PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2017-06-01 — — US disclosed
US-20170151212-A1 PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2017-06-01 — — US disclosed
US-20150030551-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2015-01-29 — — US disclosed
US-20150030551-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2015-01-29 — — US disclosed
US-8802722-B2 Benzopyran compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2014-08-12 — — US disclosed
US-8802722-B2 Benzopyran compounds as melanogenesis modifiers and uses thereof NEW YORK UNIVERSITY (US) 2014-08-12 — — US disclosed
US-20120196926-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-02 — — US disclosed
US-20120196926-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF NEW YORK UNIVERSITY 2012-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151212-A1 PRENYLATED ISOFLAVONES FOR TREATMENT OF SUBJECTS WITH MULTIDRUG-RESISTANT CANCER ABCB1, ABCC1, ABCB11 CYP3A4 437/4885MAPT 4795/4885PTPN1 3874/4885
US-20220119399-A1 COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF MYC, MYCBP, MYCBP2 CYP3A4 4830/4885MAPT 1899/4885PTPN1 2016/4885
US-20150030551-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF TYR, MITF, MC1R CYP3A4 839/4885MAPT 4033/4885PTPN1 3805/4885
US-20120196926-A1 BENZOPYRAN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF TYR, MITF, MC1R CYP3A4 839/4885MAPT 4033/4885PTPN1 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.